Vela purchased Great Basin for $1.4 million in June, and will reopen its Utah-based lab, rehire employees, and commercialize the firm's infectious disease platform.
Genoma, which is based in Italy, offers a wide range of specialty diagnostics services with an emphasis on noninvasive prenatal testing, as well as oncology tests.
Nuclea's trustee has requested the court approve sale of its assets, which failed to sell at auction, to a firm run by Nuclea's former CEO Patrick Muraca.
Set for Jan. 18, 2017, the sale will feature assets including its HER-2/neu assay, a blood-based test for monitoring women with metastatic breast cancer.
True Health will pay $37.1 million to acquire substantially all the assets of Health Diagnostic Laboratory, which is currently in Chapter 11 reorganization.
The UK's Human Fertility and Embryology Authority calls for consumer genetic testing companies to warn customers that testing could uncover family secrets, according to the Guardian.
